The Cancer Institute of New Jersey (CINJ) prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated States in our Nation. As a matrix and consortium cancer center that has been continuously funded by the NCI CCSG mechanism since 1997, CINJ conducts state of the art research, patient care, and outreach/education. CINJ is currently comprised of 161 members from a total of 32 academic departments who hold over $92.9 million total peer-reviewed support, $61.1 million annual direct support, $28.9 million total NCI support and $18.7 million annual direct NCI support (a 20% Increase in NCI support since the time of the last submission in 2004). Since the appointment of Dr. Robert S. DiPaola as center director in September, 2008, accrual onto investigator initiated therapeutic clinical trials has more than doubled; 17 new faculty were recruited in multiple areas including Basic Science, Clinical Science, Public Health Science, and Systems Biology/Bioinformatics; the Consortium relationship with Princeton University and Rutgers University was strengthened and formalized; the State's cancer registry and SEER contract was moved to CINJ; and an additional four recruitment searches were launched. CINJ now has six established Research Programs: Cell Death and Survival Signaling; Genomic Instability and Tumor Growth; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control. CINJ supports 14 Shared Resources, including: Flow Cytometry and Cell Sorting; Functional Genomics; Transgenic and Knockout Mouse; Pharmacokinetics and Pharmacodynamics; Histopathology and Imaging; Biorepository Service; Bioinformatics; Biometrics; Research Pharmacy; Office of Human Research Services; Centralized Education and Training for Clinical Research Personnel; Small Animal Imaging (developing); Metabolomics (developing) and Epidemiology Services (developing). Overall, CINJ has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has State-wide authority beyond the University matrix, thus establishing an environment to foster and formalize a Vision of Transdisciplinary and Translational Research within and beyond the University matrix. We are requesting CCSG support for Senior leadership, Program Leadership, Planning and Evaluation, Developmental Funds, Administration, Shared Resources, Protocol Review and Monitoring, Protocol Specific Research Support, and Data and Safety Monitoring.

Public Health Relevance

The mission of the CINJ is to conduct innovative basic, clinical and population research that: 1. Expands our understanding of the etiology and biology of cancer. 2. Facilitates the rapid translation of laboratory-based discoveries into human studies. 3. Develops new approaches and interventions for cancer prevention that decrease cancer incidence and mortality. 4. Develops new and better therapies to decrease suffering and mortality from cancer.(2) Fulfillment of this mission will be achieved in an environment that values diversity and fairness(3), and one that is dedicated to the development of the next generation of physicians and scientists and to delivering comprehensive and compassionate patient care.(4)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-19S4
Application #
9392943
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Roberson, Sonya
Project Start
1997-03-01
Project End
2018-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
19
Fiscal Year
2017
Total Cost
$2,651,316
Indirect Cost
$943,664
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
Organized Research Units
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Liu, Anna B; Tao, Siyao; Lee, Mao-Jung et al. (2018) Effects of gut microbiota and time of treatment on tissue levels of green tea polyphenols in mice. Biofactors :
Kim, Dae Keun; Parihar, Jaspreet Singh; Kwon, Young Suk et al. (2018) Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian J Androl 20:9-14
Shivappa, Nitin; H├ębert, James R; Paddock, Lisa E et al. (2018) Dietary inflammatory index and ovarian cancer risk in a New Jersey case-control study. Nutrition 46:78-82
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Laval, K; Vernejoul, J B; Van Cleemput, J et al. (2018) Virulent Pseudorabies Virus Infection Induces a Specific and Lethal Systemic Inflammatory Response in Mice. J Virol 92:
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Lalani, Almin I; Zhu, Sining; Xie, Ping (2018) Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay. J Vis Exp :
Warner, Wayne A; Lee, Tammy Y; Badal, Kimberly et al. (2018) Cancer incidence and mortality rates and trends in Trinidad and Tobago. BMC Cancer 18:712

Showing the most recent 10 out of 775 publications